Monkeypox Assay Kit Market Scope
Assay kits are used in life science research, drug discovery & development, and environmental monitoring in a broad range of applications such as studying disease pathways, screening for potential drug candidates, and evaluating biopharmaceutical production processes. The Monkeypox Assay kit has been developed which can help to determine the disease at right time to help government bodies and hospitals to understand the course of treatment and avoid a further pandemic. The rise in cases and technological advancement has shown growth in the market. Also, governments are expanding the laboratories to fulfill the need for more and faster tests.
Attributes | Details |
---|
Study Period | 2017-2027 |
Base Year | 2021 |
Unit | Value (USD Million) |
Key Companies Profiled | Roche (United States), Trivitron Healthcare (India), BGI Group (China), Biochain (United States), Becton Dickinson (United States), Beijing Kinghawk Pharmaceutical Co.,Ltd. (China), Shenzhen New Industries Biomedical Engineering Co., Ltd. (China), Orient Gene Biotech (China), Biotest Biotech (China) and Wondfo Biotech (China) |
CAGR | % |
The market has seen a massive investment in R&D and artificial intelligence which has driven the market growth. Massive investments and disruption of the digitization in industries due to pandemics in the market have seen a majority of providers enter the distribution channel has made it convenient to reach end-user. This has made it convenient for new entrances to grab a good position in the market as the government has shown positive support for expansion for testing infrastructure. Whereas the big players have tried to develop by mergers and acquisitions and investments in developing better technology to keep up with the competition and hold a higher position in the market. Research Analyst at AMA estimates that China Players will contribute to the maximum growth of Global Monkeypox Assay Kit market throughout the predicted period.
Roche (United States), Trivitron Healthcare (India), BGI Group (China), Biochain (United States), Becton Dickinson (United States), Beijing Kinghawk Pharmaceutical Co.,Ltd. (China), Shenzhen New Industries Biomedical Engineering Co., Ltd. (China), Orient Gene Biotech (China), Biotest Biotech (China) and Wondfo Biotech (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Shanghai Rendu Biotechnology Co Ltd (China), Beijing Bohui Innovation Biotechnology Group Co Ltd (China), Bioperfectus Technologies (China), Shanghai ZJ Bio-Tech Co., Ltd. (China) and Daan Gene (China).
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
Segmentation Overview
The study have segmented the market of Global Monkeypox Assay Kit market by Type , by Application (Hospital, Clinic and Other) and Region with country level break-up.
On the basis of geography, the market of Monkeypox Assay Kit has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
region held largest market share in the year 2021.
Market Leaders and their expansionary development strategies
Becton Dickinson has partnered with CerTest Biotec to produce a molecular diagnostic test for the monkeypox virus. This new VIASURE Monkeypox CE/IVD test will be developed using the BD MAX open system reagent suite and validated on the BD MAX system. and The BD MAX system is an automated platform for nucleic acid extraction and real-time polymerase chain reaction (PCR) testing. It can provide results for up to 24 samples within three hours, making it an exceptionally efficient means of testing.
In June 2022 Department of Health and Human Services (HHS), through the Centers for Disease Control and Prevention (CDC), began shipping orthopoxvirus tests to five commercial laboratory companies, including the nation’s largest reference laboratories, to quickly increase monkeypox testing capacity and access in every community during the ongoing monkeypox outbreak.
Influencing Trend:
There has been a Rise in the Number of Infections.
Market Growth Drivers:
Growing Investment for R&D in Pharmaceutical Industry Has Been Driving the Market.
Challenges:
High Initial Cost of Investments for R&D and The Time Taken for Approval of Devices is high.
Restraints:
Technology is Still in Development Due to Less Knowledge about Disease.
Opportunities:
Growing Development in Technology in Testing Kits to Have Better and Faster Results.
Key Target Audience
Pharmaceutical companies, New Entrants and Investors, Legalized Cannabis Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others